Nanoscope Therapeutics Press Releases
-
Positive Data from Nanoscope’s Phase 1/2a Trial of Gene Therapy to Restore Vision in Patients Blinded by Retinitis Pigmentosa to be Featured at 2021 American Society of Retina Specialists Meeting
October 8, 2021 by Nanoscope Therapeutics
-
Nanoscope President to Present at Company Showcase of the Ophthalmology Innovation Summit (OIS) Retina October 7, 2021, in San Antonio, TX
October 5, 2021 by Nanoscope Therapeutics
-
Positive Data of Optogenetic Gene Therapy for Patients Blinded by Retinitis Pigmentosa to be Presented at Retina Society’s Annual Conference
September 29, 2021 by Nanoscope Therapeutics
-
Nanoscope Awarded $1.5M Phase 2B SBIR Grant to Advance Ambient Light Activatable Opsin Gene Therapy to Restore Vision for AMD Patients
September 14, 2021 by Nanoscope Therapeutics
Nanoscope Therapeutics In the News
- Ft Worth Business Press: TechFW Client Nanoscope Receives $1.5M Grant to Move Macular Degeneration Therapy Forward
- Dallas Innovates: Nanoscope Awarded $1.5 Million Grant for Eyesight Gene Therapy as it ‘Takes Steps to Go Public’
- Journal of Cellular and Molecular Medicine: Biodistribution of adeno-associated virus type 2 carrying multi-characteristic opsin in dogs following intravitreal injection
- The Science Advisory Board: Optogenetic gene therapy provides hope for retinitis pigmentosa patients
- Fort Worth Business Press: First patient receives innovative gene therapy eye treatment from TechFW client
Upcoming Nanoscope Therapeutics Events
- Sept 10-12 2021 | Euretina
- Sept 29- Oct 2 2021 | The Retina Society 54th Annual Scientific Meeting – Chicago
- Oct 8-12 2021 | ASRS – American Society of Retina Specialists 39th Annual Scientific Meeting
- Nov 12 2021 | AAO – American Academy of Ophthalmology Annual Meeting – New Orleans
- Jan 22-27 2022 | SPIE Photonics West – San Francisco
Media Contact
Opus Biotech Communications
Daniel Eramian
daniel.eramian@comcast.net
425-306-8716
Charles Craig
charles.s.craig@gmail.com
404-245-0591
